{"preliminary_commentary":{"by_channel":{"youtube":2,"x_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"LiGeR - HN1","nct_id":"NCT06525220","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=liger-hn1-nct06525220. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Combination Therapy","label":"Petosemtamab + Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Monotherapy","label":"Pembrolizumab","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-07","type":"ESTIMATED"},"conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":{"count":699,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Petosemtamab","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Merus B.V.","official_title":"A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 3 years"},{"measure":"Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR)","timeFrame":"Up to approximately 2 years"}],"references":[{"citation":"Machiels JP, Fayette J, Haddad R, Adkins D, Gillison M, Harrington KJ, Kim SB, Le Tourneau C, Psyrri A, Rosenberg A, Siu LL, Tahara M, William WN Jr, Ford J, Jauhari S, Pyle R, Shen YM, Yao D, Zohren F, Vokes E. LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC. Future Oncol. 2025 Jul;21(16):2007-2016. doi: 10.1080/14796694.2025.2511470. Epub 2025 Jun 13.","pmid":"40511820","type":"DERIVED"}],"start_date":{"date":"2024-09-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)","url":"https://clinicaltrials.gov/study/NCT06525220"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/liger-hn1-nct06525220"}